Jubilant Sees No Material Impact From Coronavirus-Led Plant Closure, For Now
Evaluates Manufacture Of Recently Incentivized APIs
Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.
You may also be interested in...
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
After postponing foreign inspections, the US FDA has further decided to scale back domestic inspections due to the coronavirus outbreak.